The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer
Abstract The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cell-free DNA has been tested for quantity, fragmentation pattern, and tumor-specific sequences in patients with various malignancies. Recent studies have shown that cell-free DNA levels ar...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2011-03, Vol.29 (2), p.124-129 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 129 |
|---|---|
| container_issue | 2 |
| container_start_page | 124 |
| container_title | Urologic oncology |
| container_volume | 29 |
| creator | Ellinger, Jörg, M.D Müller, Stefan C., M.D Stadler, Thomas C., M.D Jung, Andreas, Ph.D von Ruecker, Alexander, M.D Bastian, Patrick J., M.D |
| description | Abstract The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cell-free DNA has been tested for quantity, fragmentation pattern, and tumor-specific sequences in patients with various malignancies. Recent studies have shown that cell-free DNA levels are distinctly increased in most patients with prostate cancer (PCA) and that the DNA fragmentation pattern is different from healthy individuals and patients with benign prostate disease. The origin of this circulating DNA remains largely unknown, but it is established that a small fraction of the DNA is derived from the tumor itself, and genetic (allelic imbalances) and epigenetic (DNA methylation) alterations are regularly detected in patients with PCA. The detection of increased DNA levels and tumor-specific DNA sequences may provide diagnostic and prognostic information. The recent findings in the emerging field of cell-free DNA will be discussed. |
| doi_str_mv | 10.1016/j.urolonc.2009.05.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_855198434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143909001574</els_id><sourcerecordid>855198434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-67436b6a3e91e2fba8e037d9b66e974b46b2298022942fb18fd18211d9dd705f3</originalsourceid><addsrcrecordid>eNqFkctu1TAQhi0Eohd4BFA2iFVSj2M78QZUlQKVqnZBEUvLsSfFh5yk2AlS356JTgQSGza2R_7_uXzD2CvgFXDQZ7tqSdMwjb4SnJuKq4oDf8KOoW3qUkijn9KbN20JsjZH7CTnHecgW4Dn7AhMo4VQ6ph9u_uOBSXCYuoLj8NQ9gmx8DH5ZXBzHO-LDzfnRRyLmYQhuvtxyjEXbgzFQ5q2iLwU5NnNZHWjx_SCPevdkPHldp-yrx8v7y4-l9e3n64uzq9LL6WZS93IWnfa1WgARd-5FnndBNNpjaaRndSdEKbldEj6hrYP0AqAYEJouOrrU_b2kJfq_1wwz3Yf8zqHG3Fasm2VAtPKWpJSHZSeOs0Je_uQ4t6lRwvcrkjtzm5I7YrUcmUJKflebxWWbo_hr2tjSII3m8Bl74Y-EYCY_-hEbTRoszbw_qBD4vErYrLZRyRYISb0sw1T_G8r7_7J4Ic4Rir6Ax8x76YljQTbgs3Ccvtl3f-6fm5o9YpQ_wY6uqtY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>855198434</pqid></control><display><type>article</type><title>The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ellinger, Jörg, M.D ; Müller, Stefan C., M.D ; Stadler, Thomas C., M.D ; Jung, Andreas, Ph.D ; von Ruecker, Alexander, M.D ; Bastian, Patrick J., M.D</creator><creatorcontrib>Ellinger, Jörg, M.D ; Müller, Stefan C., M.D ; Stadler, Thomas C., M.D ; Jung, Andreas, Ph.D ; von Ruecker, Alexander, M.D ; Bastian, Patrick J., M.D</creatorcontrib><description>Abstract The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cell-free DNA has been tested for quantity, fragmentation pattern, and tumor-specific sequences in patients with various malignancies. Recent studies have shown that cell-free DNA levels are distinctly increased in most patients with prostate cancer (PCA) and that the DNA fragmentation pattern is different from healthy individuals and patients with benign prostate disease. The origin of this circulating DNA remains largely unknown, but it is established that a small fraction of the DNA is derived from the tumor itself, and genetic (allelic imbalances) and epigenetic (DNA methylation) alterations are regularly detected in patients with PCA. The detection of increased DNA levels and tumor-specific DNA sequences may provide diagnostic and prognostic information. The recent findings in the emerging field of cell-free DNA will be discussed.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2009.05.010</identifier><identifier>PMID: 19762255</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Allelic imbalance ; Biological and medical sciences ; Biomarker ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Cell-free DNA ; CpG Islands - genetics ; DNA Methylation ; DNA, Neoplasm - blood ; DNA, Neoplasm - genetics ; Glutathione S-Transferase pi - genetics ; Humans ; Male ; Medical sciences ; Methylation ; Nephrology. Urinary tract diseases ; Prognosis ; Prostate cancer ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - genetics ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; Urology</subject><ispartof>Urologic oncology, 2011-03, Vol.29 (2), p.124-129</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-67436b6a3e91e2fba8e037d9b66e974b46b2298022942fb18fd18211d9dd705f3</citedby><cites>FETCH-LOGICAL-c449t-67436b6a3e91e2fba8e037d9b66e974b46b2298022942fb18fd18211d9dd705f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1078143909001574$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23961694$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19762255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ellinger, Jörg, M.D</creatorcontrib><creatorcontrib>Müller, Stefan C., M.D</creatorcontrib><creatorcontrib>Stadler, Thomas C., M.D</creatorcontrib><creatorcontrib>Jung, Andreas, Ph.D</creatorcontrib><creatorcontrib>von Ruecker, Alexander, M.D</creatorcontrib><creatorcontrib>Bastian, Patrick J., M.D</creatorcontrib><title>The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Abstract The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cell-free DNA has been tested for quantity, fragmentation pattern, and tumor-specific sequences in patients with various malignancies. Recent studies have shown that cell-free DNA levels are distinctly increased in most patients with prostate cancer (PCA) and that the DNA fragmentation pattern is different from healthy individuals and patients with benign prostate disease. The origin of this circulating DNA remains largely unknown, but it is established that a small fraction of the DNA is derived from the tumor itself, and genetic (allelic imbalances) and epigenetic (DNA methylation) alterations are regularly detected in patients with PCA. The detection of increased DNA levels and tumor-specific DNA sequences may provide diagnostic and prognostic information. The recent findings in the emerging field of cell-free DNA will be discussed.</description><subject>Allelic imbalance</subject><subject>Biological and medical sciences</subject><subject>Biomarker</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cell-free DNA</subject><subject>CpG Islands - genetics</subject><subject>DNA Methylation</subject><subject>DNA, Neoplasm - blood</subject><subject>DNA, Neoplasm - genetics</subject><subject>Glutathione S-Transferase pi - genetics</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylation</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>Urology</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1TAQhi0Eohd4BFA2iFVSj2M78QZUlQKVqnZBEUvLsSfFh5yk2AlS356JTgQSGza2R_7_uXzD2CvgFXDQZ7tqSdMwjb4SnJuKq4oDf8KOoW3qUkijn9KbN20JsjZH7CTnHecgW4Dn7AhMo4VQ6ph9u_uOBSXCYuoLj8NQ9gmx8DH5ZXBzHO-LDzfnRRyLmYQhuvtxyjEXbgzFQ5q2iLwU5NnNZHWjx_SCPevdkPHldp-yrx8v7y4-l9e3n64uzq9LL6WZS93IWnfa1WgARd-5FnndBNNpjaaRndSdEKbldEj6hrYP0AqAYEJouOrrU_b2kJfq_1wwz3Yf8zqHG3Fasm2VAtPKWpJSHZSeOs0Je_uQ4t6lRwvcrkjtzm5I7YrUcmUJKflebxWWbo_hr2tjSII3m8Bl74Y-EYCY_-hEbTRoszbw_qBD4vErYrLZRyRYISb0sw1T_G8r7_7J4Ic4Rir6Ax8x76YljQTbgs3Ccvtl3f-6fm5o9YpQ_wY6uqtY</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Ellinger, Jörg, M.D</creator><creator>Müller, Stefan C., M.D</creator><creator>Stadler, Thomas C., M.D</creator><creator>Jung, Andreas, Ph.D</creator><creator>von Ruecker, Alexander, M.D</creator><creator>Bastian, Patrick J., M.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer</title><author>Ellinger, Jörg, M.D ; Müller, Stefan C., M.D ; Stadler, Thomas C., M.D ; Jung, Andreas, Ph.D ; von Ruecker, Alexander, M.D ; Bastian, Patrick J., M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-67436b6a3e91e2fba8e037d9b66e974b46b2298022942fb18fd18211d9dd705f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Allelic imbalance</topic><topic>Biological and medical sciences</topic><topic>Biomarker</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cell-free DNA</topic><topic>CpG Islands - genetics</topic><topic>DNA Methylation</topic><topic>DNA, Neoplasm - blood</topic><topic>DNA, Neoplasm - genetics</topic><topic>Glutathione S-Transferase pi - genetics</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylation</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ellinger, Jörg, M.D</creatorcontrib><creatorcontrib>Müller, Stefan C., M.D</creatorcontrib><creatorcontrib>Stadler, Thomas C., M.D</creatorcontrib><creatorcontrib>Jung, Andreas, Ph.D</creatorcontrib><creatorcontrib>von Ruecker, Alexander, M.D</creatorcontrib><creatorcontrib>Bastian, Patrick J., M.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ellinger, Jörg, M.D</au><au>Müller, Stefan C., M.D</au><au>Stadler, Thomas C., M.D</au><au>Jung, Andreas, Ph.D</au><au>von Ruecker, Alexander, M.D</au><au>Bastian, Patrick J., M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>29</volume><issue>2</issue><spage>124</spage><epage>129</epage><pages>124-129</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Abstract The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cell-free DNA has been tested for quantity, fragmentation pattern, and tumor-specific sequences in patients with various malignancies. Recent studies have shown that cell-free DNA levels are distinctly increased in most patients with prostate cancer (PCA) and that the DNA fragmentation pattern is different from healthy individuals and patients with benign prostate disease. The origin of this circulating DNA remains largely unknown, but it is established that a small fraction of the DNA is derived from the tumor itself, and genetic (allelic imbalances) and epigenetic (DNA methylation) alterations are regularly detected in patients with PCA. The detection of increased DNA levels and tumor-specific DNA sequences may provide diagnostic and prognostic information. The recent findings in the emerging field of cell-free DNA will be discussed.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19762255</pmid><doi>10.1016/j.urolonc.2009.05.010</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2011-03, Vol.29 (2), p.124-129 |
| issn | 1078-1439 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_855198434 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allelic imbalance Biological and medical sciences Biomarker Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cell-free DNA CpG Islands - genetics DNA Methylation DNA, Neoplasm - blood DNA, Neoplasm - genetics Glutathione S-Transferase pi - genetics Humans Male Medical sciences Methylation Nephrology. Urinary tract diseases Prognosis Prostate cancer Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - genetics Tumors Tumors of the urinary system Urinary tract. Prostate gland Urology |
| title | The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T16%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20cell-free%20circulating%20DNA%20in%20the%20diagnosis%20and%20prognosis%20of%20prostate%20cancer&rft.jtitle=Urologic%20oncology&rft.au=Ellinger,%20J%C3%B6rg,%20M.D&rft.date=2011-03-01&rft.volume=29&rft.issue=2&rft.spage=124&rft.epage=129&rft.pages=124-129&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2009.05.010&rft_dat=%3Cproquest_cross%3E855198434%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=855198434&rft_id=info:pmid/19762255&rft_els_id=S1078143909001574&rfr_iscdi=true |